

1 **Heart-retina time analysis using electrocardiogram-coupled time-**  
2 **resolved dynamic optical coherence tomography**

3

4 Philippe Valmaggia, <sup>1,2,3,\*</sup> Julia Wolleb,<sup>1</sup> Florentin Bieder,<sup>1</sup> Hendrik P.N. Scholl,<sup>3</sup>

5 Philippe C. Cattin<sup>1,†</sup> Peter M. Maloca <sup>2,3,†</sup>

6

7 <sup>1</sup> Department of Biomedical Engineering, University of Basel, Hegenheimermattweg  
8 167b/c, 4123 Allschwil, Switzerland

9 <sup>2</sup> Institute of Molecular and Clinical Ophthalmology Basel (IOB), Mittlere Strasse 91,  
10 4056 Basel, Switzerland

11 <sup>3</sup> Department of Ophthalmology, University Hospital Basel, Mittlere Strasse 91, 4031  
12 Basel, Switzerland

13 \* philippe.valmaggia@unibas.ch

14 † These authors contributed equally to this work.

15 **Corresponding author:** Philippe Valmaggia, Department of Biomedical  
16 Engineering, University of Basel, 4123 Allschwil, Switzerland.

17 E-mail: philippe.valmaggia@unibas.ch

18 **Abstract**

19 The eye and the heart are two closely interlinked organs, and many diseases  
20 affecting the cardiovascular system manifest in the eye. To contribute to the  
21 understanding of blood flow propagation towards the retina, we developed a method  
22 to acquire electrocardiogram (ECG) coupled time-resolved dynamic optical  
23 coherence tomography (OCT) images. This method allows for continuous  
24 synchronised monitoring of the cardiac cycle and retinal blood flow dynamics. The  
25 dynamic OCT measurements were used to calculate time-resolved blood flow  
26 profiles using fringe washout analysis. The relative fringe washout was computed to  
27 generate the flow velocity profiles within arterioles at the optic nerve head rim. We  
28 found that the blood column between the heart and the retina propagates within one  
29 cardiac cycle, denoting the arrival time as the heart-retina time (HRT). In a group of  
30 healthy subjects, the HRT was  $144 \pm 19$  ms (mean  $\pm$  SD). The HRT could provide a  
31 novel potential biomarker for cardiovascular health in direct relation to retinal  
32 perfusion.

## 33 Introduction

34 The eye and the heart are closely connected <sup>1-3</sup>. The cardiovascular system plays a  
35 crucial role in delivering blood to the eye. The blood travels through a sequence of  
36 arteries, including the carotid, ophthalmic, and central retinal arteries, until it reaches  
37 the retina. The fine bed of capillary structures guarantees the delivery of nutrients at  
38 the retina, which is essential for maintaining the visual function. Perturbances of  
39 blood flow towards the eye can cause ischemic occlusions or haemorrhages,  
40 ultimately leading to vision loss <sup>4-7</sup>. The heart's function can be analysed with the  
41 electrocardiogram (ECG), precisely measuring the cardiac rhythm and anomalies <sup>8</sup>.  
42 Analysing the cardiac cycle enables us to detect the moment of contraction of the  
43 ventricles, which leads to the blood being pumped towards the corporal circulation.  
44 The eye, specifically the retina, can be imaged with optical coherence tomography  
45 (OCT) <sup>9</sup>. OCT allows for a non-invasive assessment of ocular structures and  
46 generates high-resolution images on a micrometre scale <sup>10</sup>. Recent developments in  
47 OCT have enabled us to measure OCT dynamically, even with devices approved for  
48 routine clinical use <sup>11</sup>. These dynamic OCT acquisitions allow the estimation of  
49 dynamic flow profiles within vessels of the retinal vasculature and were suggested to  
50 represent a propagation of the cardiac cycle pulsation <sup>11</sup>. These time-resolved  
51 dynamic blood flow profiles surpass certain limitations of optical coherence  
52 tomography angiography (OCTA) providing qualitative perfusion maps, variable  
53 inter-scan time analysis (VISTA) providing quantitative single-velocity (per vessel)  
54 perfusion maps, or laser speckle flowgraphy (LSFG) providing en-face flow profiles  
55 <sup>12-14</sup>. The time-resolved dynamic OCT acquisitions allow a depth-resolved flow  
56 profile analysis with a temporal resolution as fast as 101 Hz per B-scan for an  
57 acquisition with 125 kHz per A-scan on B-scans with 1024 A-scans.

58

59 However, the propagation of the cardiac pulse wave is poorly understood because  
60 the cardiac and retinal acquisitions are not synchronised. Coupling devices could  
61 provide additional information about potential mismatches between the cardiac cycle  
62 pulse waves and the pulse waves recorded at the retinal level. To this end, we  
63 investigated the feasibility of linked acquisitions by coupling an ECG to a time-  
64 resolved OCT device. The importance of timestamp matching must be emphasised  
65 here, which is why it was decided to acquire the ECG information with an open-  
66 source device capable of recording the ECG signal with microsecond precision. The  
67 time-resolved OCT images have integrated timestamps, which we can use to match  
68 the two time series. Both clocks were synchronised using a network time protocol  
69 (NTP) server.

70

71 We aimed to generate a new option to analyse information regarding the propagation  
72 of cardiac pulsations towards the eye by linking the information of the ECG to the  
73 time-resolved OCT. Knowledge about the propagation velocity of the cardiac pulse  
74 wave could be helpful in finding potential turbulences in the pathway and give a  
75 general overview of cardiovascular health, and specifically, risks for cardiovascular  
76 disturbances manifesting in the retina. We introduce the heart-retina time (HRT),  
77 which represents the time the blood column needs to propagate from the heart to the  
78 eye. We further aim to present with this work the feasibility of ECG-coupled time-  
79 resolved OCT acquisitions, the correlation between the cardiac cycle and retinal  
80 pulse waves and the potential of the HRT as a biomarker.

81

## 82 **Methods**

### 83 **Study design and patient population**

84 This was a cross-sectional observational cohort study in healthy subjects. The  
85 inclusion criteria contained an age of at least 18 years and no history of vascular  
86 diseases or ophthalmic surgery. Further, the participants did not smoke or drink  
87 coffee six hours before the measurements to prevent possible effects on the retinal  
88 microvasculature <sup>15</sup>. Each subject was informed about the study and written informed  
89 consent was obtained. The study was approved by the Ethics Committee  
90 Northwestern and Central Switzerland (EKNZ\_2021-02360) and performed in  
91 accordance with the declaration of Helsinki.

92

### 93 **Hardware description**

94 The OCT device used for this study was a Spectralis (Heidelberg Engineering  
95 GmbH, Heidelberg, Germany). The device allowed for a modification of the scan  
96 patterns and the integration time with an investigational acquisition module <sup>16,17</sup>. The  
97 ECG device used for this study was the open-source vitals monitor Healthy Pi v4.4  
98 with a 3-lead ECG (Protocentral, Bangalore, India). The Healthy Pi v4.4, based on  
99 an ESP32 microprocessor, had the capability to record ECGs with a temporal  
100 frequency of 125 Hz <sup>18</sup>. The Arduino code was modified to include timestamps with a  
101 microsecond precision into the same data packet as the ECG samples <sup>19</sup>. Power  
102 supply and data transfer were done with a high-speed micro-USB 2.0 cable and  
103 connected to the same computer as the Spectralis. The programming of the ECG  
104 was performed with the Arduino language in IDE V 1.8.13 and a graphical user  
105 interface was generated with Processing V 3.5.4.



## 121 **Data acquisition**

122 The demographic characteristics of the study subjects (age, sex, height) were  
123 obtained from the study subjects before the measurements. An example OCT  
124 volume was acquired to familiarise the study subjects with the OCT device and the  
125 specific fixation target. Following this initial test, the patients were connected to the  
126 ECG device and seated in front of the OCT. Timestamp synchronisation was  
127 performed and tested before the acquisitions started.

128

129 Three-lead ECG acquisitions were started, and data were continuously recorded to a  
130 .csv file, including the timestamps with a microseconds precision and the ECG  
131 voltage in arbitrary units generated by the HealthyPi (HP value). The OCT  
132 acquisition module was then initiated, and the patient asked to remain calm and  
133 fixate on the blue cross target provided by the manufacturer. An equal illumination of  
134 the scanning laser ophthalmoscopy (SLO) in all image areas was verified and the  
135 acquisition location of the B-Scan was steered to the desired position. Continuous B-  
136 scans were then acquired at the superior and inferior optic nerve head rims of both  
137 eyes. The nominal acquisition line-scan rate was set to 20 or 85 kHz, corresponding  
138 to an integration time of 44.8 or 11.2  $\mu$ s, respectively. The B-scans were  
139 continuously acquired for approximately 7 seconds with a scan pattern of 1024  $\times$  496  
140 pixels on a field-of-view (FOV) of 10°. In case of blinks or bad signal quality, the  
141 recorded data were not used for further analysis.

## 142 Data processing

143 The ECG data were resampled to fixed interval timestamps at the 125 Hz acquisition  
144 rate with linear interpolation for missing ECG values. Following this, the R-Peaks of  
145 the ECG were extracted using the “EngZee” algorithm with an implementation in  
146 Python <sup>21,22</sup>. The binary R-Peak signals were then smoothed using a Gaussian filter  
147 ( $\sigma = 1.25$ ) and the values afterwards normalised between 0 and 1. The heart rate  
148 was then given by the R-Peaks.

149

150 The OCT data were exported in RAW format (.vol). Each of the B-scans was  
151 matched with a timestamp with milliseconds precision. The timestamps were  
152 exported with the corresponding image included in the .vol file header. Pixel  
153 intensities in the .vol format are stored in normalised values between 0 and 1. For  
154 visualisation purposes, these pixel intensities were transformed for each as  $V(x,y) =$   
155  $255 \times \sqrt[4]{I(x,y)}$ , where  $V(x,y)$  denotes the pixel intensity for visualisation at  
156 coordinates  $(x,y)$  and  $I(x,y)$  denotes the normalised original intensity.

157

158 As a first step after intensity transformation, the B-scans were registered with a rigid  
159 transformation using a pyramid processing framework <sup>23</sup>. The framework was  
160 modified and an average of the first ten images of each time series image stack was  
161 taken as reference image for the registration of the B-scans on each other. The  
162 annotation of the vessel centres was then manually performed. For this, the  
163 registered volumes were loaded as 3D image stacks into 3D Slicer V4.11. The  
164 arterial centres were manually annotated as landmarks in each single B-Scan. The  
165 vessel centres were identified by 1) identifying the horizontal centres point by



166 identifying the shadow behind the vessel, and 2) Identifying the anterior-posterior  
167 centres by identifying the centre between the hyperreflective vessel walls <sup>24</sup>.

168

169 Subareas surrounding the arteriole centres of 7×7 pixels (corresponding to ~20×27  
170 μm) were then extracted along the time series. Inside these subareas, the signal-to-  
171 noise ratio SNR was calculated by dividing the average signal intensity of the  
172 subarea divided by the noise level of the B-scan. Assuming shot-noise limited  
173 detection, the B-scan noise level was approximated by dividing the maximum  
174 intensity extracted from the raw data by the Heidelberg Quality score. The SNR for  
175 the subarea of each B-Scan was calculated as:

176

$$\text{SNR}_{\text{Subarea}_i} = \frac{1}{W_i \times H_i} \times \left( \sum_{x=1}^{W_i} \sum_{y=1}^{H_i} I_i(x, y) \right) \times \frac{1}{\frac{\max(I_i)}{Q_i} \times 10^{10}}, \quad (1)$$

179 where  $i$  denotes the index of the B-scan,  $I(x, y)$  denotes the intensity at the coordinates  
180  $(x, y)$ . The width and height of the subarea are denoted as  $w$  and  $h$ .  $\max_i I_i$  denotes the  
181 maximum intensity obtained from the metadata of the B-scan, and  $Q$  denotes the  
182 Heidelberg Quality score in decibel (dB). Each  $i$ -th B-scan was matched to a  
183 timestamp with ms precision, which was also stored in the metadata.

184 The SNR of each subarea was then compared with a reference SNR to calculate the  
185 drop in SNR ( $\text{SNR}_{\text{Drop}}$ ). As reference level, the peak SNR on a pixel level was  
186 chosen. The  $\text{SNR}_{\text{Drop}}$  was used to calculate relative flow velocity profiles according to  
187 <sup>11,25</sup>.

188

$$\text{SNR}_{\text{Drop}} = \frac{\sin(k_0 \Delta z)^2}{(k_0 \Delta z)^2}, \quad (2)$$

191

192 where  $k_0 = 2 * \pi / \lambda$  and  $\Delta z = n * v * \tau$ . The equation was solved numerically for  $v$ , the  
193 velocity of the axial component of the motion. In these equations,  $k_0$  denotes the  
194 central wavenumber,  $\lambda$  is the central wavelength of the light source,  $\Delta z$  corresponds  
195 to the displacement in the z-axis,  $n$  is the eye's refractive index, and  $\tau$  denotes the  
196 integration time. Multiple possible solutions exist, and every numerical solution  
197 calculated for each B-scan was stored as a potential flow velocity.

198

199 The pulse wave analyses for the correlation with the cardiac cycle were performed  
200 with the envelope function of the maximal numerical solution of Eq. (2). Local  
201 maxima of the first derivative of the flow profile were taken to identify the sharpest  
202 rises of the blood flow velocity, representing the arrival time of the pulse propagation  
203 at the retina. The local maxima were identified within the time series bins correlating  
204 to the heart rate, which was identified by the ECG. These local maxima were then  
205 processed in the same way as the R-Peaks: They were binarised along the time axis  
206 as single time points, and the Gaussian filter ( $\sigma = 1.25$ ) was applied, followed by a  
207  $[0, 1]$  normalisation.

208

209 The timelines of the ECG R-Peaks and the pulse arrival times of the time-resolved  
210 OCT data were then compared with cross-correlations. This was used to calculate  
211 the lag between the two time series, where the OCT time series served as the  
212 baseline for the cross-correlation. The ECG data was extracted from 10 seconds  
213 prior to the first B-scan of the time-resolved OCT data until 1 second after the last B-  
214 scan. The lag values were then sorted according to the argmax of the cross-  
215 correlation values to identify the most probable offset between the moment of the  
216 contraction of the heart ventricles (ECG R-Peaks) and the arrival at the retina  
217 (sharpest rise in OCT blood flow velocity profile).

218

219 The HRT was then denominated for the time needed for the arrival at the retina. This  
220 time corresponds to the time the impulse to the blood column needs to arrive from  
221 the contraction of the left cardiac ventricle, as identified by the R-Peak at the retina.  
222 This pulse propagation times aim to reveal information about the rigidity of the  
223 vessels. Hence, information about the functioning of the cardiovascular system can  
224 be obtained by combining recordings of the electrical heart activity with an ECG and  
225 imaging of the retina with structural OCT.

226

227 The timestamp synchronisation of the OCT and the ECG was performed via  
228 timestamp synchronisation with the NTP server, including an offset correction for  
229 asymmetric network synchronisation between both devices. Several  
230 synchronisations have been completed within the same network to assess the  
231 reliability. The programming tasks for image analysis were carried out using Linux  
232 shell scripts, Python 3.9 (Python Software Foundation, Wilmington, USA), and R

233 V4.2.2 (developed by the Foundation for Statistical Computing, Vienna, Austria). For  
234 data visualisation, Python 3.9, R V4.2.2, and 3DSlicer V4.11 were used <sup>26</sup>.

235

## 236 **Statistical analysis**

237 The statistical analysis focused on different aspects of the data. First, we analysed  
238 the flow velocity profiles, including the acquisition characteristics, the calculated  
239 velocities and the SNR. The correlation with the ECG data was then analysed  
240 qualitatively by plotting the time series and quantitatively with cross-correlations. The  
241 reproducibility of the HRT was assessed for intra-subject, inter-subject, intra-exam,  
242 and intra-vessel variability. These variabilities were analysed with the coefficient of  
243 variation (CoV). Descriptive values in this manuscript are presented as mean  $\pm$   
244 standard deviation (SD) or median [interquartile-range (IQR)].

245

## 246 **Results**

### 247 **Feasibility of coupled ECG and time-resolved OCT acquisitions**

248 The synchronous ECG and OCT data acquisition, including timestamp  
249 synchronisation, was feasible and well-tolerated in all subjects. Two subjects were  
250 female, and three were male. The subjects were 24 to 32 years old and healthy. In  
251 total, 90 arterioles were analysed in 70 acquisitions at the optic nerve head. In right  
252 eye acquisitions (n=47), 25 arterioles have been analysed at the superior part of the  
253 optic nerve head and 22 at the inferior part. In left eye acquisitions, 23 arterioles have  
254 been analysed at the superior part and 20 at the inferior part. 54 arterioles from 39  
255 acquisitions have been acquired at a nominal A-scan rate of 20 kHz, and 36 arterioles  
256 from 31 acquisitions have been acquired at a nominal A-scan rate of 85 kHz. From  
257 these acquisitions, a total of 26'100 arteriole centres have been manually annotated  
258 in all B-scans combined. Further information about the acquisition parameters can be  
259 found in Table 1, including an overview of the calculated velocity flow profiles.

260

261 The matching of the OCT and the ECG device is visualised in Figure 2 as a  
262 screenshot. The corresponding recording can be found in Supplementary Video 1. It  
263 shows the processed data, including the registered time-resolved OCT B-scans, the  
264 corresponding ECG trace and the acquisition position of the B-scan on the SLO image.  
265 The B-scan size in pixels, the FOV and the conversion to real size were extracted from  
266 the metadata of the .vol files. The ECG data is presented with the time elapsed since  
267 the last R-Peak as well as the percentage of the current cardiac cycle completed.  
268 Minor eye movements during the acquisition occurred. The registration process can  
269 compensate for motion in the anterior-posterior and fast-scanning directions. This can  
270 be identified through the black boxes at the border of the images. However,

271 movements that were non-collinear with the fast-scanning direction could not be  
 272 compensated as eye tracking was disabled.

273

274


275

**Table 1. Acquisition overview per nominal A-scan rate**

	<b>20 kHz, n = 54</b>	<b>85 kHz, n = 36</b>
<b>Exam Duration [ms]</b>	7144 (6908, 7480)	6879 (6879, 6880)
<b>Annotated B-scans per Image Stack [n]</b>	145 (140, 152)	512 (512, 512)
<b>SNR<sub>B-scan</sub> [dB]</b>	42.0 (40.2, 44.1)	36.1 (34.4, 37.7)
<b>Peak B-scan Intensity [RAW value × 10<sup>6</sup>]</b>	1037.4 (756.1, 1470.4)	954.2 (737.7, 1610.7)
<b>Vessel Intensity [RAW value × 10<sup>6</sup>]</b>	7.9 (2.4, 61.8)	49.6 (19.9, 129.3)
<b>SNR<sub>Vessel</sub> / Peak SNR<sub>Vessel</sub> [%]</b>	2.1 (1.5, 3.3)	2.5 (1.7, 3.2)
<b>Average Velocity [a.u.]</b>	14 (10, 17)	48 (41, 58)
<b>Minimal Velocity [a.u.]</b>	5.8 (5.6, 5.9)	24.1 (23.6, 24.5)
<b>Maximal Velocity [a.u.]</b>	22 (15, 29)	73 (59, 92)

Results are presented as median (IQR) of the average values per image stack

n: number of time-resolved image stacks; SNR: signal-to-noise ratio; SNR<sub>B-scan</sub>: SNR in the complete B-scan; SNR<sub>Vessel</sub>: Average SNR in the vessel subareas of the B-Scan; Peak SNR<sub>Vessel</sub>: maximum SNR on a pixel level in the complete vessel subarea, corresponding to the reference SNR for velocity calculations; RAW value: value extracted from the raw .vol OCT files; a.u.: arbitrary unit; IQR: interquartile range.




276  
277

**Fig. 2.** Overview of an ECG-coupled dynamic time-resolved OCT acquisition.

278 The upper half of the image shows the B-scan that corresponds to the specific moment in the cardiac cycle. The  
279 cardiac cycle is indicated in the bottom left, where the red vertical line indicates the current moment. The red  
280 arrow in the image on the bottom right shows the acquisition location of the B-scan. FOV: field of view. SLO:  
281 Scanning laser ophthalmoscopy, ECG: electrocardiogram, HP value: Healthy Pi ECG voltage values.

## 282 **Correlation between the cardiac cycle and retinal pulse waves**

283 Supplementary Video 1 shows the clear pulsatile intensity changes at the centre of the  
284 arterioles at the inferior part of the optic nerve head. These pulsatile intensity changes  
285 due to fringe washout reflect changes in the flow speed within the retinal vessels <sup>11</sup>.  
286 The pulsations in the calculated blood flow profiles corresponded in frequency to  
287 the heart rate. The envelope function of the maximal calculated flow velocity allowed  
288 to identify the local sharpest rises of the pulse wave. The sharpest rises of the pulse  
289 wave were used to determine the arrival of the pulse wave at the retina. The plotting  
290 of the sharpest rise and the R-Peaks revealed that both peaks occurred with relative  
291 constant lags.



292  
293

**Fig. 3.** Peak signal extraction from OCT and ECG data.

294 The time since OCT acquisition start on the x-axis is the same for all subfigures. The first plot shows the average  
295 signal-to-noise ratio (SNR) in the extracted subareas ( $\mu 7 \times 7$  pixels) over time. The second plot shows the  
296 calculated axial flow velocity values based on fringe washout, where the NSI represents the numerical solution  
297 index. The third plot shows the velocity gradient of the envelope function of the second subplot, where the  
298 sharpest rise is automatically detected. The fourth plot shows the ECG signal from the HealthyPi (HP) with  
299 detected R-Peaks. The detected peaks from both ECG and OCT are then plotted on top of each other in the fifth  
300 plot.




301 The example OCT subarea SNR, the calculated axial flow velocity profiles, the  
302 velocity gradients with the sharpest rise, and the ECG trace with the R-Peaks are  
303 visualised in Figure 3 for the right artery (A1) of the Supplementary Video 1.  
304 Supplementary Video 2 show another example of ECG-coupled OCT at the optic  
305 nerve head. The ocular blood flow pulsations match in frequency with the heart beat.

306

307 The calculated axial flow profiles are represented as a scatter plot, where each B-  
308 scan is represented as a pillar of scatters on the x-axis. Each numerical solution to  
309 the  $SNR_{Drop}$  equation is represented as a scatter, where the index of the numerical  
310 solution is indicated in the colormap. The velocity gradient is calculated for the  
311 envelope function of the maximal calculated flow velocity. The sharpest rises are  
312 hence depicted as the local maxima of the first derivative of this envelope function.  
313 The “EngZee” algorithm provided reliable detection of the R-Peaks in the ECG trace.

314

315 The timepoints of these signals were encoded as binary information with Gaussian  
316 smoothing to allow for uncertainty in the signal detection. The cross-correlation of both  
317 signals enabled to determine the most probable delay for the HRT. The ECG data was  
318 padded 10 seconds before the start and 1 second after the end of the OCT signal. The  
319 normalised cross-correlation of both signals showed the expected intermittent spikes  
320 where the  $\text{argmax}$  of the signal corresponded to the most probable peak. Figure 4  
321 visualises the normalised cross-correlation of both signals, showing the most probable  
322 offset of the ECG to the OCT at -136 ms, which corresponds to a HRT of 136 ms.  
323 These findings showed that the R-Peaks and the sharpest rises of the pulse waves  
324 correlated well.



325

326 **Fig. 4.** Signal analysis for the determination of the heart-retina time (HRT).

327 The top row shows the R-Peaks from the ECG signal, the middle row shows the times of the sharpest rise in the

328 OCT flow velocity signal and the bottom row shows the normalised cross-correlation of both signals. The ECG

329 signal has been extended for 10s before the start and 1s after the end of the OCT signal. The highest peak in the

330 normalised cross-correlation represents the most probable offset of the ECG towards the OCT signal,

331 representing the additive inverse of the HRT.

332

### 333 **The heart-retina time as a potential biomarker**


334 The first step to calculate the HRT was to find out how many pulse waves are on the

335 way from the heart to the eye. As seen in Figure 4, the cross-correlation signals are

336 repetitive peaks that occur due to the pulsatile nature of the velocity peaks. The

337 argmax of this function provided the most probable offset for each of the 90 annotated


338 vessels. Figure 5a shows a clearly distinguishable mode of the cross-correlation  
339 histogram at the bin of -150 to -100 ms. This indicates that the blood column between  
340 the heart and the retina is propagated within one heart cycle.



341  
342 **Fig. 5.** Heart-retina time (HRT) results overview. **a** Histogram plot with a bin width of 50ms for the argmax of the  
343 cross-correlation signals showing that the most probable delay between the R-Peak and the arrival of the pulse is  
344 within one cardiac cycle. **b** HRTs of the five included subjects showing good intrasubject and inter-subject  
345 reproducibility. **c-f** HRTs of different acquisitions within the same vessels.

346 The HRT was then calculated for each of the acquisition time series with the argmax  
347 of the cross-correlation signal within one heartbeat, the results further apart being  
348 identified as outliers. The HRT is shown as the additive inverse of the calculated offset.  
349 The HRT showed good intersubject and intrasubject reproducibility. The HRT of all  
350 acquisitions was  $144 \pm 19$  ms (mean  $\pm$  SD). A visualisation of the measurements for  
351 each subject can be found in Figure 4b. The intersubject CoV was 0.09, and the  
352 intrasubject CoV was  $0.11 \pm 0.03$ .

353 Figure 5c-f shows the results of several acquisitions where more than one vessel was  
354 annotated. Each subplot represents one acquisition location and each Exam ID  
355 represents one time series. The intra-exam CoV in case more than one vessel was  
356 annotated was  $0.07 \pm 0.04$ . The intra-vessel CoV in case the HRT was calculated in  
357 more than one exam was  $0.09 \pm 0.05$ . Supplementary Video 3 shows a representation  
358 of an acquisition where three arterioles were annotated and evaluated to calculate the  
359 HRT. The video visually shows the synchronous arrival of the pulse waves in all three  
360 annotated arterioles. In Figure 6, the available information from an ECG-coupled time-  
361 resolved dynamic OCT with three annotated arterioles is shown.



362  
363

364 **Fig. 6.** Overview of the information available in ECG-coupled dynamic time-resolved OCT, showing an acquisition  
365 with blood flow profiles from three annotated arterioles (A1, A2, A3). The identification of the arterioles in the OCT  
366 was made on the corresponding SLO image. The blood flow profiles show synchronous pulsatility, corresponding  
367 in frequency with the cardiac cycle over the synchronous acquisition of 7 seconds. The analysis of the delay allows  
368 to calculate the HRT for all of the annotated vessels

## 369 Discussion

370 In this study, we developed a method to link the cardiac cycle to the blood flow  
371 pulsations in the retina. We connected a commercially available OCT device to an  
372 open-source ECG and merged the acquisitions via synchronised timestamps.  
373 Pulsatility was found in the OCT flow velocity profiles, and the sharpest rises of the  
374 pulse waves were identified. These peaks were cross-correlated with the R-Peaks  
375 from the ECG. We found that the blood column between the heart and the retina  
376 propagates within one cardiac cycle. Via an analysis of the lag between the two  
377 signals, we can calculate the HRT. We propose this HRT as a potential new biomarker  
378 for the analysis of cardiovascular health.

379

380 Cardiovascular diseases, including hypertension, frequently manifest in both the heart  
381 and the eye<sup>1</sup>. Conditions like hypertensive retinopathy, which can result in vision loss,  
382 are examples of this interconnectedness<sup>27</sup>. Many ideas have been developed to  
383 identify systemic diseases from the eye by gaining information about the vascular state  
384<sup>28,29</sup>. Few studies have been conducted to link the heart and the eye via ECG to assess  
385 the pulsatile vessel calibre on fundus photographs or with ultrasound to assess the  
386 larger carotid or ophthalmic arteries in synchronicity with the heart<sup>30-33</sup>. To the best of  
387 our knowledge, we present the first link of an ECG with OCT to assess retinal blood  
388 flow profiles.

389

390 With this method, we showed that the blood flow propagates towards the retina within  
391 one cardiac cycle. This finding might be counterintuitive initially as the arm-retina time  
392 from fundus fluorescein angiography (FFA) is in the range of 7-15 seconds<sup>34</sup>. In FFA,  
393 a dye bolus is injected into the arm of the patient and then propagated towards the

394 peripheral circulation. The fluorescein is mainly bound to human serum proteins after  
395 injection<sup>35,36</sup>. For the FFA arrival time, the dye hence travels at the same speed as  
396 the particles in the blood. In our study using ECG-coupled OCT analysis, we observed  
397 significantly shorter delay times for the HRT. This result can be described similarly to  
398 a hose filled with water: when the water pump is activated, water begins to flow out of  
399 the hose almost instantly, rather than requiring the water to traverse the entire length  
400 of the hose. When the pump is restarted, water starts almost immediately to flow out  
401 of the hose opening, without the water having to travel all the way through the hose.  
402 Hence, we hypothesise that we rather measure the propagation of the blood column  
403 instead of the propagation speed of single blood particles.

404

405 The assessment of blood flow in conjunction with the heart has been explored in  
406 several other fields, with a particular focus on the pulse transit time<sup>37-39</sup>. The pulse  
407 transit time measures the time taken for blood to travel between two locations in the  
408 body. The transit time for the blood to travel from the heart, as measured from the R-  
409 Peak in the ECG, to the carotid artery has been measured at  $100 \pm 11$  ms<sup>32</sup>. The  
410 pulse transit times for the blood to arrive from the heart to the ear, finger, and toe have  
411 been measured at 126, 269, and 266 ms, respectively<sup>40</sup>. The measured HRT of  $144$   
412  $\pm 19$  ms is well compatible with these previous findings.

413

414 Pulse transit times, in general, have been shown to correlate well with blood pressure  
415 and have often been suggested as an additional biomarker, extending or even  
416 substituting cuff-based blood pressure measurements<sup>38,39,41</sup>. The pulse wave velocity  
417 can be calculated by dividing the distance between the two measurements by the  
418 pulse transit time<sup>42</sup>. Shorter pulse transit times hence correspond to faster pulse wave



419 velocities, and faster pulse wave velocities are found in stiffer arteries<sup>43</sup>. The analysis  
420 of pulse wave velocity can not only be used to estimate the blood pressure but also to  
421 assess target organ damage<sup>44</sup>. Faster pulse wave velocities have been found to be  
422 associated with the risk of stroke and to be predictive of cerebrovascular events<sup>45</sup>. As  
423 the retina shares a significant proportion of the perfusing vessels with the rest of the  
424 brain, the HRT has the potential to lead to a better understanding of the pulse wave  
425 propagation towards arterioles perfusing the central nervous system.

426

427 With the proposed HRT, we aim to contribute to the field of pulse arrival times. The  
428 HRT in this first feasibility study showed good intra-subject, inter-subject, intra-exam  
429 and intra-vessel reproducibility. The intra-subject, inter-subject and intra-vessel  
430 variabilities were in a very similar range. We estimate these variations to be  
431 attributable to noise and natural variability, which could be similar to the heart-rate  
432 variability. The heart-rate variability can be used for an objective assessment of stress  
433<sup>46</sup>. The intra-exam CoV showed the lowest variability, however, it was still existent.  
434 This variability between different vessels in the same examination comes through  
435 different pulse wave forms in the OCT flow profiles, as the identified R-Peaks are the  
436 same for all within the same examination. The further exploration of HRT variability,  
437 particularly its relationship with heart-rate variability, could help differentiate between  
438 random fluctuations and inherent variability. In further investigations of HRT variability,  
439 valuable information about the propagation of blood flow could be gained.

440

441 The study has limitations of different origins. One is the small number of subjects  
442 included in the study. This was partly compensated by the repetitive acquisition and  
443 will be further addressed by generating normative databases in a larger population in



444 the future. Future work will also expand the study populations to include subjects with  
445 cardiovascular diseases to evaluate and validate the potential of the HRT as a  
446 biomarker. Another factor is the synchronisation mechanism, which consists of a  
447 calibration of the PC and ECG time series via NTP. In the future, mechanisms to use  
448 the same clock for the ECG and OCT could be investigated. In this work, we were  
449 limited by the used devices, which did not allow for a direct access of the clock of the  
450 other instrument, potentially leading to a HRT biases between different acquisitions. A  
451 further limitation is the time-consuming analysis procedure of single arteriole centres.  
452 However, the 26'100 annotated vessel centres from this study could serve as the basis  
453 for the development of automated landmark detection systems, alleviating the manual  
454 burden.

455

456 Our study's main strength is that we developed a method with a widely used  
457 commercially available OCT device. Second, the ECG device we used is based on an  
458 open-source device, which would allow for an easy integration with different OCT  
459 devices. Hence, this means that the method can be used and reproduced in other  
460 settings, where time-resolved OCT acquisitions are feasible. Third, we propose a  
461 quantitative method to assess the cardiovascular state. Similar to other pulse wave  
462 velocity methods, we provide a specific method for the propagation from the heart to  
463 the eye. Future studies will assess the validation and clinical usability of the HRT as a  
464 biomarker for cardiovascular health.

## 465 **Conclusions**

466 In this study, we propose a method to analyse the propagation of blood flow from the  
467 heart to the retina. We demonstrated the feasibility of ECG-coupled time-resolved  
468 OCT acquisitions and the correlation between the cardiac cycle and retinal pulse  
469 waves. The cross-correlation of the ECG and the blood flow profiles in retinal  
470 arterioles revealed the propagation of the blood column within a cardiac cycle. By  
471 analysing the lag between the two signals, the HRT can be calculated. The  
472 investigation of blood flow propagation is an important field to better understand  
473 vascular turbulences. The synchronised acquisition of ECG with dynamic OCT offers  
474 a method to explore cardiovascular and ocular health interconnections. This study  
475 establishes the foundation for utilising the HRT as a potential biomarker in evaluating  
476 systemic and ocular vascular conditions.

## 477 References

- 478 1. Flammer, J. *et al.* The eye and the heart. *Eur Heart J* **34**, 1270–1278 (2013).
- 479 2. Chatterjee, S., Chattopadhyaya, S., Hope-Ross, M. & Lip, P. L. Hypertension and the eye:  
480 changing perspectives. *Journal of Human Hypertension* **2002 16:10 16**, 667–675 (2002).
- 481 3. Farrah, T. E., Dhillon, B., Keane, P. A., Webb, D. J. & Dhaun, N. The eye, the kidney, and  
482 cardiovascular disease: old concepts, better tools, and new horizons. *Kidney International* vol.  
483 98 323–342 Preprint at <https://doi.org/10.1016/j.kint.2020.01.039> (2020).
- 484 4. Brown, G. C., Shah, H. G., Magargal, L. E. & Savino, P. J. Central Retinal Vein Obstruction  
485 and Carotid Artery Disease. *Ophthalmology* **91**, 1627–1633 (1984).
- 486 5. Wong, T. Y. *et al.* Retinal Microvascular Abnormalities and their Relationship with  
487 Hypertension, Cardiovascular Disease, and Mortality. *Surv Ophthalmol* **46**, 59–80 (2001).
- 488 6. Wong, T. Y. *et al.* Retinal microvascular abnormalities and incident stroke: The Atherosclerosis  
489 Risk in Communities Study. *Lancet* **358**, 1134–1140 (2001).
- 490 7. Kewcharoen, J. *et al.* Prevalence of Atrial Fibrillation in Patients with Retinal Vessel Occlusion  
491 and Its Association: A Systematic Review and Meta-Analysis. *Curr Eye Res* **44**, 1337–1344  
492 (2019).
- 493 8. Martis, R. J., Acharya, U. R. & Adeli, H. Current methods in electrocardiogram  
494 characterization. *Comput Biol Med* **48**, 133–149 (2014).
- 495 9. Huang, D. *et al.* Optical coherence tomography. *Science (1979)* **254**, 1178–1181 (1991).
- 496 10. Fujimoto, J. & Swanson, E. The development, commercialization, and impact of optical  
497 coherence tomography. *Investigative Ophthalmology and Visual Science* vol. 57 OCT1–  
498 OCT13 Preprint at <https://doi.org/10.1167/iovs.16-19963> (2016).
- 499 11. Valmaggia, P. *et al.* Time-Resolved Dynamic Optical Coherence Tomography for Retinal  
500 Blood Flow Analysis. *Invest Ophthalmol Vis Sci* **65**, 9–9 (2024).
- 501 12. Spaide, R. F., Fujimoto, J. G., Waheed, N. K., Sadda, S. R. & Staurengi, G. Optical  
502 coherence tomography angiography. *Prog Retin Eye Res* **64**, 1–55 (2018).
- 503 13. Ploner, S. B. *et al.* Toward quantitative optical coherence tomography angiography: Visualizing  
504 blood flow speeds in ocular: Pathology using variable interscan time analysis. in *Retina* vol. 36  
505 S118–S126 (NIH Public Access, 2016).
- 506 14. Hwang, Y. *et al.* Retinal blood flow speed quantification at the capillary level using temporal  
507 autocorrelation fitting OCTA [Invited]. *Biomed Opt Express* **14**, 2658 (2023).
- 508 15. Dogan, M., Akdogan, M., Sabaner, C. & Gobeka, H. H. Morphological changes in  
509 retinochoroidal microvasculature after caffeinated versus decaffeinated coffee consumption ☆.  
510 *Photodiagnosis Photodyn Ther* **40**, 1572–1000 (2022).
- 511 16. Spaide, R. F. *et al.* Imaging the vitreous with a novel boosted optical coherence tomography  
512 technique: Vitreous degeneration and cisterns. *Retina* **42**, 1433–1441 (2022).
- 513 17. Spaide, R. F., Valmaggia, P. & Maloca, P. M. IMAGING the VITREOUS with A NOVEL  
514 BOOSTED OPTICAL COHERENCE TOMOGRAPHY TECHNIQUE: Posterior Vitreous  
515 Detachment. *Retina* **42**, 1425–1432 (2022).
- 516 18. Thilagavathy, R. *et al.* Real-Time ECG Signal Feature Extraction and Classification using  
517 Support Vector Machine. *2020 International Conference on Contemporary Computing and  
518 Applications, IC3A 2020* 44–48 (2020) doi:10.1109/IC3A48958.2020.233266.

- 519 19. Ashwin K Whitchurch et al. HealthyPi v4 Arduino Library.  
520 [https://github.com/Protocentral/protocentral\\_healthypi4\\_arduino](https://github.com/Protocentral/protocentral_healthypi4_arduino) (2021).
- 521 20. Bernier, L. G., Dudle, G. & Schlunegger, C. METAS time & frequency metrology report. in  
522 *Proceedings of the IEEE International Frequency Control Symposium and Exposition* vol. 2005  
523 213–216 (Institute of Electrical and Electronics Engineers Inc., 2005).
- 524 21. Porr, B. & Howell, L. R-peak detector stress test with a new noisy ECG database reveals  
525 significant performance differences amongst popular detectors. *bioRxiv* 722397 (2019)  
526 doi:10.1101/722397.
- 527 22. Engelse, W. A. H. & Zeelenberg, C. A single scan algorithm for QRS-detection and feature  
528 extraction. *Comput Cardiol* **6**, 37–42 (1979).
- 529 23. Thévenaz, P., Ruttimann, U. E. & Unser, M. A pyramid approach to subpixel registration based  
530 on intensity. *IEEE Transactions on Image Processing* **7**, 27–41 (1998).
- 531 24. Lou, W. *et al.* Comparison of Two Spectral-domain Optical Coherence Tomography Scan  
532 Modes for Measuring Retinal Vessel Diameter.  
533 <https://doi.org/10.1080/02713683.2020.1862238> **46**, 1025–1030 (2021).
- 534 25. Yun, S. H., Tearney, G. J., de Boer, J. F. & Bouma, B. E. Motion artifacts in optical coherence  
535 tomography with frequency-domain ranging. *Opt Express* **12**, 2977 (2004).
- 536 26. Fedorov, A. *et al.* 3D Slicer as an image computing platform for the Quantitative Imaging  
537 Network. *Magn Reson Imaging* **30**, 1323–1341 (2012).
- 538 27. Wong, T. Y. & Mitchell, P. Hypertensive Retinopathy. <https://doi.org/10.1056/NEJMra032865>  
539 **351**, 2310–2317 (2004).
- 540 28. Zhou, Y. *et al.* AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep  
541 Learning Pipeline. *Transl Vis Sci Technol* **11**, 12–12 (2022).
- 542 29. Wagner, S. K. *et al.* Insights into Systemic Disease through Retinal Imaging-Based Oculomics.  
543 *Transl Vis Sci Technol* **9**, (2020).
- 544 30. Saruhan, Y., Bollinger, O. & Gugleta, K. Analysis of Retinal Vessel Pulsation with  
545 Electrographic Gating - Pulsation Amplitude and the Influence of Hyperoxia. *Klin Monbl*  
546 *Augenheilkd* **237**, 469–473 (2020).
- 547 31. Bollinger, O., Saruhan, Y. & Gugleta, K. Analysis of Retinal Vessel Pulsations with  
548 Electrocardiographic Gating. *Klin Monbl Augenheilkd* **237**, 464–468 (2020).
- 549 32. Salvi, P. *et al.* Systolic time intervals assessed from analysis of the carotid pressure waveform.  
550 *Physiol Meas* **39**, 084002 (2018).
- 551 33. Katamay, R., Fleischlin, C., Gugleta, K., Flammer, J. & Orgül, S. Volumetric blood flow  
552 measurement in the ophthalmic artery using colour Doppler. *Klin Monbl Augenheilkd* **226**,  
553 249–253 (2009).
- 554 34. Littlewood, R., Mollan, S. P., Pepper, I. M. & Hickman, S. J. The Utility of Fundus Fluorescein  
555 Angiography in Neuro-Ophthalmology. *Neuro-Ophthalmology* vol. 43 217–234 Preprint at  
556 <https://doi.org/10.1080/01658107.2019.1604764> (2019).
- 557 35. Rockey, J. H., Li, W. & Eccleston, J. F. Binding of fluorescein and carboxyfluorescein by  
558 human serum proteins: Significance of kinetic and equilibrium parameters of association in  
559 ocular fluorometric studies. *Exp Eye Res* **37**, 455–466 (1983).
- 560 36. Penniston, J. T. Fluorescence polarization measurement of binding of fluorescein to albumin.  
561 *Exp Eye Res* **34**, 435–443 (1982).

- 562 37. Pour Ebrahim, M. *et al.* Blood Pressure Estimation Using On-body Continuous Wave Radar  
563 and Photoplethysmogram in Various Posture and Exercise Conditions. *Sci Rep* **9**, (2019).
- 564 38. Vischer, A. S. & Burkard, T. Principles of blood pressure measurement – current techniques,  
565 office vs ambulatory blood pressure measurement. in *Advances in Experimental Medicine and*  
566 *Biology* vol. 956 85–96 (Springer New York LLC, 2017).
- 567 39. Muehlsteff, J., Aubert, X. L. & Schuett, M. Cuffless estimation of systolic blood pressure for  
568 short effort bicycle tests: The prominent role of the pre-ejection period. in *Annual International*  
569 *Conference of the IEEE Engineering in Medicine and Biology - Proceedings* 5088–5092  
570 (2006). doi:10.1109/IEMBS.2006.260275.
- 571 40. Block, R. C. *et al.* Conventional pulse transit times as markers of blood pressure changes in  
572 humans. *Sci Rep* **10**, 1–9 (2020).
- 573 41. Ding, X. R., Zhang, Y. T., Liu, J., Dai, W. X. & Tsang, H. K. Continuous Cuffless Blood  
574 Pressure Estimation Using Pulse Transit Time and Photoplethysmogram Intensity Ratio. *IEEE*  
575 *Trans Biomed Eng* **63**, 964–972 (2016).
- 576 42. Ding, X. & Zhang, Y. T. Pulse transit time technique for cuffless unobtrusive blood pressure  
577 measurement: from theory to algorithm. *Biomedical Engineering Letters* vol. 9 37–52 Preprint  
578 at <https://doi.org/10.1007/s13534-019-00096-x> (2019).
- 579 43. Huttunen, J. M. J., Kärkkäinen, L. & Lindholm, H. Pulse transit time estimation of aortic pulse  
580 wave velocity and blood pressure using machine learning and simulated training data. *PLoS*  
581 *Comput Biol* **15**, (2019).
- 582 44. Chao, H., Wang, Q., Avolio, A. & Zuo, J. COMPARISON OF INFLUENCE OF OFFICE PULSE  
583 WAVE VELOCITY AND 24-HOUR AMBULATORY RECORDING OF AORTIC PULSE WAVE  
584 VELOCITY ON TARGET DAMAGE IN HYPERTENSION. *J Hypertens* **41**, e266 (2023).
- 585 45. Jae, S. Y., Heffernan, K. S., Kurl, S., Kunutsor, S. K. & Laukkanen, J. A. Association between  
586 estimated pulse wave velocity and the risk of stroke in middle-aged men. *International Journal*  
587 *of Stroke* **16**, 551–555 (2021).
- 588 46. Kim, H. G., Cheon, E. J., Bai, D. S., Lee, Y. H. & Koo, B. H. Stress and Heart Rate Variability:  
589 A Meta-Analysis and Review of the Literature. *Psychiatry Investig* **15**, 235 (2018).
- 590
- 591

592 **Acknowledgments**

593 This study received funding via personal grants to PV from the Swiss National Science  
594 Foundation (Grant 323530\_199395), AlumniMedizin Basel and the Janggen-Pöhn  
595 Foundation. In addition, the researchers would like to thank all the participants who  
596 volunteered for this study.

597

598 **Author contributions**

599 PV: Conceptualisation, methodology, software, validation, formal analysis,  
600 investigation, resources, data acquisition, data processing, writing (original draft  
601 preparation), writing (review and editing), visualisation and project administration.

602 JW: Methodology, software, validation, formal analysis, investigation, writing (review  
603 and editing).

604 FB: Methodology, software, validation, formal analysis, investigation, writing (review  
605 and editing).

606 HPNS: Methodology, validation, investigation, resources, writing (review and editing)  
607 and project administration.

608 PCC: Conceptualisation, methodology, software, validation, formal analysis,  
609 investigation, resources, data processing, writing (original draft preparation), writing  
610 (review and editing) and project administration.

611 PMM: Conceptualisation, methodology, validation, formal analysis, investigation,  
612 resources, data processing, writing (original draft preparation), writing (review and  
613 editing), visualisation and project administration.

614 **Ethics declarations**

615 PV received speaker fees from Heidelberg Engineering GmbH and Bayer.

616 HPNS is supported by the Swiss National Science Foundation (Project funding:  
617 “Developing novel outcomes for clinical trials in Stargardt disease using  
618 structure/function relationship and deep learning” #310030\_201165, and National  
619 Center of Competence in Research Molecular Systems Engineering: “NCCR MSE:  
620 Molecular Systems Engineering (phase II)” #51NF40-182895, the Wellcome Trust  
621 (PINNACLE study), and the Foundation Fighting Blindness Clinical Research  
622 Institute (ProgStar study). Dr. Scholl is member of the Scientific Advisory Board of:  
623 Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences;  
624 Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH;  
625 ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant  
626 of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global,  
627 LLC; and Tenpoint Therapeutics. Dr. Scholl is member of the Data Monitoring and  
628 Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304; LBS-008-  
629 CT02, NCT05266014), F. Hoffmann-La Roche Ltd (VELODROME trial,  
630 NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial), ViGeneron (protocol  
631 number VG901-2021-A) and member of the Steering Committee of Novo Nordisk  
632 (FOCUS trial; NCT03811561).

633 PMM is a consultant of Roche and holds intellectual properties for machine learning  
634 at MIMO AG and VisionAI, Switzerland.

635 The other authors declare no conflict. Funding organisations had no influence on the  
636 design, performance or evaluation of the current study.

637 **Data availability**

638 The data presented in this paper are not publicly available due to data protection  
639 regulations. Interested parties may request access to the data from the  
640 corresponding author (PV) upon reasonable request and approval from the  
641 concerned institutional review boards.

642

643 **Supplementary Material**

644 **Supplementary Video 1**

645 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography at  
646 the optic nerve head. The pulsatile intensity changes at the centre of the arterioles  
647 are due to fringe washout.

648 **Supplementary Video 2**

649 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography of  
650 an arteriole with synchronised velocity profile and electrocardiogram trace at the  
651 optic nerve head. The ocular blood flow pulsations match in frequency with the heart  
652 beat.

653 **Supplementary Video 3**

654 Electrocardiogram-coupled time-resolved dynamic optical coherence tomography of  
655 three arterioles with synchronised velocity profiles and electrocardiogram trace at the  
656 optic nerve head. The ocular blood flow pulsations match in frequency. The arrival  
657 time can be calculated and is denoted as the heart-retina time.